Anika Therapeutics, Inc., a joint preservation company, focuses on early intervention orthopedics in the United States, Europe, and internationally. The company offers osteoarthritis (OA) pain management products and services, such as Monovisc and Orthovisc, which are single- and multi-injection, HA viscosupplement products indicated for pain relief from OA conditions, as well as Cingal, a non-opioid, single-injection OA pain management product; regenerative solutions, including an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; Hyalofast, a resorbable scaffold used for single stage cartilage regeneration; and Tactoset injectable bone substitute, an HA-enhanced injectable bone repair therapy designed to treat insufficiency fractures and augment hardware fixation. It also provides Integrity, an HA-based scaffold with bone and tendon fixation components and arthroscopic delivery instruments; non-orthopedic products, including Hyvisc, a high molecular weight injectable HA veterinary product for the treatment of joint dysfunction in horses due to non-infectious synovitis associated with equine OA; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and ophthalmic products; and Anikavisc and Nuvisc high molecular weight HA products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.…
Anika Therapeutics Inc (ANIK) Q3 2026 Earnings Call Highlights: Revenue Growth and Margin Gains ...
Anika Therapeutics (NASDAQ: ANIK) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 235 employees.
The shares were at 13.23 USD on 20 November 2026, up 34.3% over 52 weeks. Its 52-week range is 9.010 USD to 22.88 USD: the price is 42.2% below the high and 46.8% above the low.
Its market capitalisation is 177.22M USD.
Anika Therapeutics reports return on equity of -7.6%, an operating margin of -0.1% and revenue up 10.0% year over year.
It holds more cash than debt, a net cash position of 18.81M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 2 analysts cover the stock, with an average rating of Buy; their mean price target of 20.00 USD is 51.2% above the current price. The next earnings report is expected on 25 February 2027.